Baron Silver Stevens Financial Advisors LLC Has $793,000 Position in Johnson & Johnson (NYSE:JNJ)

Baron Silver Stevens Financial Advisors LLC decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 1.3% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 5,482 shares of the company’s stock after selling 74 shares during the period. Baron Silver Stevens Financial Advisors LLC’s holdings in Johnson & Johnson were worth $793,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Endeavor Private Wealth Inc. bought a new stake in Johnson & Johnson in the fourth quarter valued at $50,000. Raleigh Capital Management Inc. grew its holdings in shares of Johnson & Johnson by 48.3% in the 4th quarter. Raleigh Capital Management Inc. now owns 14,773 shares of the company’s stock worth $2,136,000 after purchasing an additional 4,810 shares during the last quarter. Asset Planning Services Inc. LA ADV increased its position in shares of Johnson & Johnson by 3.1% during the 4th quarter. Asset Planning Services Inc. LA ADV now owns 37,224 shares of the company’s stock worth $5,383,000 after purchasing an additional 1,120 shares in the last quarter. True North Advisors LLC boosted its position in Johnson & Johnson by 2.9% in the fourth quarter. True North Advisors LLC now owns 9,046 shares of the company’s stock valued at $1,308,000 after buying an additional 253 shares in the last quarter. Finally, Janney Montgomery Scott LLC grew its stake in Johnson & Johnson by 10.3% during the fourth quarter. Janney Montgomery Scott LLC now owns 1,292,787 shares of the company’s stock worth $186,963,000 after buying an additional 120,815 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of the company’s stock in a transaction dated Thursday, December 12th. The shares were bought at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the transaction, the director now directly owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

Shares of JNJ opened at $146.76 on Friday. The stock has a market cap of $353.34 billion, a P/E ratio of 22.07, a price-to-earnings-growth ratio of 2.45 and a beta of 0.51. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The stock’s 50-day moving average price is $147.85 and its two-hundred day moving average price is $155.99. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The business had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22,438,500 billion. During the same quarter last year, the firm earned $2.29 EPS. Johnson & Johnson’s quarterly revenue was up 5.3% compared to the same quarter last year. On average, equities analysts predict that Johnson & Johnson will post 10.56 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.38%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s payout ratio is presently 74.59%.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on JNJ shares. Raymond James reduced their target price on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a report on Thursday. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday. Citigroup reduced their price target on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Stifel Nicolaus lowered their price objective on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research report on Thursday. Finally, Wolfe Research began coverage on shares of Johnson & Johnson in a research report on Friday, November 15th. They set an “outperform” rating and a $190.00 target price on the stock. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average price target of $170.06.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.